Quantitative structure-pharmacokinetic/pharmacodynamic relationships

Advanced Drug Delivery Reviews

Volumn 58, Issue 12-13, 2006, Pages 1326-1356

  Mager, Donald E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Absorption; Distribution; Excretion; Metabolism; Molecular modeling; Pharmacokinetic pharmacodynamic modeling; Protein binding; QSAR; QSPR

Indexed keywords

ABSORPTION; BIOASSAY; DRUG PRODUCTS; METABOLISM; PHARMACODYNAMICS;

EXCRETION; MOLECULAR MODELING; PROTEIN BINDING; QUANTITATIVE STRUCTURE-PK RELATIONSHIPS (QSPKR);

DRUG THERAPY;

ADENOSINE A1 RECEPTOR AGONIST; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; DEXAMETHASONE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; STEROID; TRIAMCINOLONE ACETONIDE; TRICYCLIC ANTIDEPRESSANT AGENT;

BIOASSAY; BIOLOGICAL ACTIVITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; GASTROINTESTINAL ABSORPTION; HUMAN; LIPOPHILICITY; MATHEMATICAL MODEL; MOLECULAR MODEL; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTITATIVE STRUCTURE PROPERTY RELATION; REVIEW;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PHARMACOKINETICS; PHARMACOLOGY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33751176669     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.08.002     Document Type: Review

References (179)

1. Abdel-Rahman S.M., and Kauffman R.E. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 111-136
2. Hansch C., and Leo A. Exploring QSAR. Fundamentals and Applications in Chemistry and Biology (1995), American Chemical Society, Washington
3. Van de Waterbeemd H. Hydrophobicity of Organic Compounds (1986), CompuDrug International, Vienna
4. Hansch C., and Fujita T. Rho-sigma-pi analysis. A method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc. 86 (1964) 1616-1626
5. Smith D.A., Van de Waterbeemd H., and Walker D.K. Pharmacokinetics and Metabolism in Drug Design (2001), Wiley-VCH, New York
6. Meyer H. Zur Theories der Alkoholnarkose. 1. Welche Eigenschaft der Anasthetica bedingt ihre narkotische Wirkung?. Arch. Exp. Pathol. Pharmakol. 42 (1899) 109-118
7. Overton E. Uber die osmotischen Eigenschaften der Zelle in ihrer Bedeutung fur die Toxikologie und Pharmakologie. Z. Phys. Chem. 22 (1897) 189-209
8. Free Jr. S.M., and Wilson J.W. A mathematical contribution to structure-activity studies. J. Med. Chem. 53 (1964) 395-399
9. Fujita T., and Ban T. Structure-activity study of phenethylamines as substrates of biosynthetic enzymes of sympathetic transmitters. J. Med. Chem. 14 (1971) 148-152
10. Hansch C., and Dunn III W.J. Linear relationships between lipophilic character and biological activity of drugs. J. Pharm. Sci. 61 (1972) 1-19
11. Collander R. Partition of organic compounds between higher alcohols and water. Acta Chem. Scand. 5 (1951) 774-780
12. Hansch C., and Clayton J.M. Lipophilic character and biological activity of drugs. II. The parabolic case. J. Pharm. Sci. 62 (1973) 1-21
13. Higuchi T., and Davis S.S. Thermodynamic analysis of structure-activity relationships of drugs: prediction of optimal structure. J. Pharm. Sci. 59 (1970) 1376-1383
14. McFarland J.W. On the parabolic relationship between drug potency and hydrophobicity. J. Med. Chem. 13 (1970) 1192-1196
15. Kubinyi H. Quantitative structure-activity relationships. IV. Non-linear dependence of biological activity on hydrophobic character: a new model. Arzneim.-Forsch. 26 (1976) 1991-1997
16. Kubinyi H. Drug partitioning: relationships between forward and reverse rate constants and partition coefficient. J. Pharm. Sci. 67 (1978) 262-263
17. Balaz S., Wiese M., and Seydel J.K. A time hierarchy-based model for kinetics of drug disposition and its use in quantitative structure-activity relationships. J. Pharm. Sci. 81 (1992) 849-857
18. Balaz S., Pirselova K., Schultz T.W., and Hermens J. Kinetics of subcellular distribution of multiply ionizable compounds: a mathematical description and its use in QSAR. J. Theor. Biol. 178 (1996) 7-16
19. Dvorsky R., Balaz S., and Sawchuk R.J. Kinetics of subcellular distribution of compounds in simple biosystems and its use in QSAR. J. Theor. Biol. 185 (1997) 213-222
20. Buchwald P. General linearized biexponential model for QSAR data showing bilinear-type distribution. J. Pharm. Sci. 94 (2005) 2355-2379
21. Aarons L., Bell D., Waigh R., and Ye Q. Parabolic structure-activity relationships: a simple pharmacokinetic model. J. Pharm. Pharmacol. 34 (1982) 746-749
22. Karelson M. Molecular Descriptors in QSAR/QSPR (2000), John Wiley & Sons, Inc., New York
23. El Tayar N., Tsai R.S., Testa B., Carrupt P.A., and Leo A. Partitioning of solutes in different solvent systems: the contribution of hydrogen-bonding capacity and polarity. J. Pharm. Sci. 80 (1991) 590-598
24. Meylan W.M., and Howard P.H. Atom/fragment contribution method for estimating octanol-water partition coefficients. J. Pharm. Sci. 84 (1995) 83-92
25. Taskinen J., and Yliruusi J. Prediction of physicochemical properties based on neural network modeling. Adv. Drug Deliv. Rev. 55 (2003) 1163-1183
26. Tetko I.V., and Bruneau P. Application of ALOGPS to predict 1-octanol/water distribution coefficients, logP, and logD, of AstraZeneca in-house database. J. Pharm. Sci. 93 (2004) 3103-3110
27. Testa B., Carrupt P.A., Gaillard P., Billois F., and Weber P. Lipophilicity in molecular modeling. Pharm. Res. 13 (1996) 335-343
28. Kier L.B. Molecular Orbital Theory in Drug Research vol. 10 (1971), Academic Press, Inc., New York
29. Taft R.W. Polar and steric substituent constants for aliphatic and o-benzoate groups from rates of esterification and hydrolysis of esters. J. Am. Chem. Soc. 74 (1952) 3120-3128
30. Connolly M.L. Solvent-accessible surfaces of proteins and nucleic acids. Science 221 (1983) 709-713
31. Kier L.B., and Hall L.H. Molecular Connectivity in Chemistry and Drug Research (1976), Academic Press, Inc., New York
32. Geladi P., and Kowalski B. Partial least-squares regression: a tutorial. Anal. Chim. Acta 185 (1986) 1-17
33. Cramer III R.D., Patterson D.E., and Bunce J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110 (1988) 5959-5967
34. Klebe G., Abraham U., and Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 37 (1994) 4130-4146
35. Erb R.J. Introduction to backpropagation neural network computation. Pharm. Res. 10 (1993) 165-170
36. Agatonovic-Kustrin S., and Beresford R. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. J. Pharm. Biomed. Anal. 22 (2000) 717-727
37. Winkler D.A. Neural networks as robust tools in drug lead discovery and development. Mol. Biotechnol. 27 (2004) 139-168
38. Bailer-Jones C.A.L., MacKay D.J.C., and Withers P.J. A recurrent neural network for modelling dynamical systems. Netw. Comput. Neural Syst. 9 (1998) 531-547
39. Neal R.M. Bayesian Learning for Neural Networks (1996), Springer-Verlag, New York
40. Burden F.R. Quantitative structure-activity relationship studies using Gaussian processes. J. Chem. Inf. Comput. Sci. 41 (2001) 830-835
41. Stouch T.R., Kenyon J.R., Johnson S.R., Chen X.Q., Doweyko A., and Li Y. In silico ADME/Tox: why models fail. J. Comput. Aided Mol. Des. 17 (2003) 83-92
42. Seydel J.K., and Schaper K.J. Quantitative structure-pharmacokinetic relationships and drug design. Pharmacol. Ther. 15 (1981) 131-182
43. Austel V., and Kutter E. Absorption, distribution, and metabolism of drugs. In: Topliss J.G. (Ed). Quantitative Structure-Activity Relationships of Drugs (1983), Academic Press, Inc., New York 437-496
44. Mayer J.M., and van de Waterbeemd H. Development of quantitative structure-pharmacokinetic relationships. Environ. Health Perspect. 61 (1985) 295-306
45. Ekins S., Waller C.L., Swaan P.W., Cruciani G., Wrighton S.A., and Wikel J.H. Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods 44 (2000) 251-272
46. van de Waterbeemd H., and Gifford E. ADMET in silico modelling: towards prediction paradise?. Nat. Rev. Drug Discov. 2 (2003) 192-204
47. Yamashita F., and Hashida M. In silico approaches for predicting ADME properties of drugs. Drug Metab. Pharmacokinet. 19 (2004) 327-338
48. Martinez M.N., and Amidon G.L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. 42 (2002) 620-643
49. Cummins C.L., Jacobsen W., and Benet L.Z. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 300 (2002) 1036-1045
50. Amidon G.L., Lennernaes H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
51. Wu C.Y., and Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005) 11-23
52. Wagner J.G., Northam J.I., Alway C.D., and Carpenter O.S. Blood levels of drug at the equilibrium state after multiple dosing. Nature 207 (1965) 1301-1302
53. Jusko W.J. Guidelines for collection and analysis of pharmacokinetic data. In: Evans W.E., Schentag J.J., and Jusko W.J. (Eds). Applied Pharmacokinetics (1992), Applied Therapeutics, Inc., Vancouver p. Ch. 2.
54. Watari N., Sugiyama Y., Kaneniwa N., and Hiura M. Prediction of hepatic first-pass metabolism and plasma levels following intravenous and oral administration of barbiturates in the rabbit based on quantitative structure-pharmacokinetic relationships. J. Pharmacokinet. Biopharm. 16 (1988) 279-301
55. Wagner J.G. Biopharmaceutics and Relevant Pharmacokinetics (1971), Drug Intelligence Publications, Hamilton
56. Kubinyi H. Lipophilicity and biological activity. Drug transport and drug distribution in model systems and in biological systems. Arzneimittelforschung 29 (1979) 1067-1080
57. Bermejo M., Merino V., Garrigues T.M., Pla Delfina J.M., Mulet A., Vizet P., Trouiller G., and Mercier C. Validation of a biophysical drug absorption model by the PATQSAR system. J. Pharm. Sci. 88 (1999) 398-405
58. Camenisch G., Folkers G., and van de Waterbeemd H. Review of theoretical passive drug absorption models: historical background, recent developments and limitations. Pharm. Acta Helv. 71 (1996) 309-327
59. Camenisch G., Folkers G., and van de Waterbeemd H. Shapes of membrane permeability-lipophilicity curves: extension of theoretical models with an aqueous pore pathway. Eur. J. Pharm. Sci. 6 (1998) 325-329
60. Dressman J.B., Amidon G.L., and Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J. Pharm. Sci. 74 (1985) 588-589
61. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
62. Palm K., Stenberg P., Luthman K., and Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14 (1997) 568-571
63. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci. 88 (1999) 807-814
64. Veber D.F., Johnson S.R., Cheng H.Y., Smith B.R., Ward K.W., and Kopple K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45 (2002) 2615-2623
65. Kelder J., Grootenhuis P.D., Bayada D.M., Delbressine L.P., and Ploemen J.P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16 (1999) 1514-1519
66. Johnson S.R., and Zheng W. Recent progress in the computational prediction of aqueous solubility and absorption. AAPS J 8 (2006) E27-E40
67. Stenberg P., Luthman K., Ellens H., Lee C.P., Smith P.L., Lago A., Elliott J.D., and Artursson P. Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity. Pharm. Res. 16 (1999) 1520-1526
68. Liu H.X., Hu R.J., Zhang R.S., Yao X.J., Liu M.C., Hu Z.D., and Fan B.T. The prediction of human oral absorption for diffusion rate-limited drugs based on heuristic method and support vector machine. J. Comput. Aided Mol. Des. 19 (2005) 33-46
69. Hirono S., Nakagome I., Hirano H., Matsushita Y., Yoshii F., and Moriguchi I. Non-congeneric structure-pharmacokinetic property correlation studies using fuzzy adaptive least-squares: oral bioavailability. Biol. Pharm. Bull. 17 (1994) 306-309
70. Andrews C.W., Bennett L., and Yu L.X. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm. Res. 17 (2000) 639-644
71. Turner J.V., Maddalena D.J., and Agatonovic-Kustrin S. Bioavailability prediction based on molecular structure for a diverse series of drugs. Pharm. Res. 21 (2004) 68-82
72. Pintore M., Van de Waterbeemd H., Piclin N., and Chretien J.R. Prediction of oral bioavailability by adaptive fuzzy partitioning. Eur. J. Med. Chem. 38 (2003) 427-431
73. Yoshida F., and Topliss J.G. QSAR model for drug human oral bioavailability. J. Med. Chem. 43 (2000) 2575-2585
74. Zmuidinavicius D., Didziapetris R., Japertas P., and Avdeef A. Classification structure-activity relations (C-SAR) in prediction of human intestinal absorption. J. Pharm. Sci. 92 (2003) 621-633
75. MacKichan J.J. Influence of protein binding and use of unbound (free) drug concentrations. In: Evans W.E., Schentag J.J., and Jusko W.J. (Eds). Applied Pharmacokinetics (1992), Applied Therapeutics, Inc., Vancouver p. Ch. 5.
76. Wilkinson G.R. Plasma and tissue binding considerations in drug disposition. Drug Metab. Rev. 14 (1983) 427-465
77. Ebling W.F., Milsap R.L., Szefler S.J., and Jusko W.J. 6 alpha-Methylprednisolone and 6 alpha-methylprednisone plasma protein binding in humans and rabbits. J. Pharm. Sci. 75 (1986) 760-763
78. Bohl M. Theoretical investigations on steroid structure and quantitative structure-activity relationships. In: Bohl M., and Duax W.L. (Eds). Molecular Structure and Biological Activity of Steroids (1992), CRC Press, Inc., Boca Raton 91-155
79. Toon S., and Rowland M. Structure-pharmacokinetic relationships among the barbiturates in the rat. J. Pharmacol. Exp. Ther. 225 (1983) 752-763
80. Van der Graaf P.H., Nilsson J., Van Schaick E.A., and Danhof M. Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat. J. Pharm. Sci. 88 (1999) 306-312
81. Mager D.E., and Jusko W.J. Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. J. Pharm. Sci. 91 (2002) 2441-2451
82. Colmenarejo G., Alvarez-Pedraglio A., and Lavandera J.L. Cheminformatic models to predict binding affinities to human serum albumin. J. Med. Chem. 44 (2001) 4370-4378
83. Gobburu J.V., and Shelver W.H. Quantitative structure-pharmacokinetic relationships (QSPR) of beta blockers derived using neural networks. J. Pharm. Sci. 84 (1995) 862-865
84. Turner J.V., Maddalena D.J., and Cutler D.J. Pharmacokinetic parameter prediction from drug structure using artificial neural networks. Int. J. Pharm. 270 (2004) 209-219
85. Yap C.W., and Chen Y.Z. Quantitative structure-pharmacokinetic relationships for drug distribution properties by using general regression neural network. J. Pharm. Sci. 94 (2005) 153-168
86. Gillette J. Factors affecting drug metabolism. Ann. N. Y. Acad. Sci. 179 (1971) 43-66
87. Lin J.H., Cocchetto D.M., and Duggan D.E. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin. Pharmacokinet. 12 (1987) 402-432
88. Balant-Gorgia A.E., Balant L.P., and Andreoli A. Pharmacokinetic optimisation of the treatment of psychosis. Clin. Pharmacokinet. 25 (1993) 217-236
89. Hinderling P.H. Drug distribution in the body: in vitro prediction and physiological interpretation. Prog. Pharmacol. 6 (1988) 1-30
90. Davis A.M., Webborn P.J.H., and Salt D.W. Robust assessment of statistical significance in the use of unbound/intrinsic pharmacokinetic parameters in quantitative structure-pharmacokinetic relationships with lipophilicity. Drug Metab. Dispos. 28 (2000) 103-106
91. Herman R.A., and Veng-Pedersen P. Quantitative structure-pharmacokinetic relationships for systemic drug distribution kinetics not confined to a congeneric series. J. Pharm. Sci. 83 (1994) 423-428
92. Hirono S., Nakagome I., Hirano H., Yoshii F., and Moriguchi I. Non-congeneric structure-pharmacokinetic property correlation studies using fuzzy adaptive least-squares: volume of distribution. Biol. Pharm. Bull. 17 (1994) 686-690
93. Lombardo F., Obach R.S., Shalaeva M.Y., and Gao F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J. Med. Chem. 45 (2002) 2867-2876
94. Oie S., and Tozer T.N. Effect of altered plasma protein binding on apparent volume of distribution. J. Pharm. Sci. 68 (1979) 1203-1205
95. Ghafourian T., Barzegar-Jalali M., Hakimiha N., and Cronin M.T.D. Quantitative structure-pharmacokinetic relationship modeling: apparent volume of distribution. J. Pharm. Pharmacol. 56 (2004) 339-350
96. Wajima T., Fukumura K., Yano Y., and Oguma T. Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: volume of distribution at steady state. J. Pharm. Pharmacol. 55 (2003) 939-949
97. Ng C., Xiao Y., Putnam W., Lum B., and Tropsha A. Quantitative structure-pharmacokinetic parameters relationships (QSPKR) analysis of antimicrobial agents in humans using simulated annealing k-nearest neighbor and partial least-square analysis methods. J. Pharm. Sci. 93 (2004) 2535-2544
98. Turner J.V., Maddalena D.J., Cutler D.J., and Agatonovic-Kustrin S. Multiple pharmacokinetic parameter prediction for a series of cephalosporins. J. Pharm. Sci. 92 (2003) 552-559
99. Ritschel W.A., Akileswaran R., and Hussain A.S. Application of neural networks for the prediction of human pharmacokinetic parameters. Methods Find. Exp. Clin. Pharmacol. 17 (1995) 629-643
100. ss quantitative structure-activity relationship models. J. Med. Chem. 49 (2006) 1953-1963
101. Hinderling P.H., Schmidlin O., and Seydel J.K. Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man. J. Pharmacokinet. Biopharm. 12 (1984) 263-287
102. Gibaldi M., and Perrier D. Pharmacokinetics (1982), Marcel Dekker, Inc., New York
103. Hall S., and Rowland M. Relationship between renal clearance, protein binding and urine flow for digitoxin, a compound of low clearance in the isolated perfused rat kidney. J. Pharmacol. Exp. Ther. 228 (1984) 174-179
104. Wesson L.G. A theoretical analysis of urea excretion by the mammalian kidney. Am. J. Physiol. 179 (1954) 364-371
105. Mayer J.M., Hall S.D., and Rowland M. Relationship between lipophilicity and tubular reabsorption for a series of 5-alkyl-5-ethylbarbituric acids in the isolated perfused rat kidney preparation. J. Pharm. Sci. 77 (1988) 359-364
106. Saville B.A., Gray M.R., and Tam Y.K. Models of hepatic drug elimination. Drug Metab. Rev. 24 (1992) 49-88
107. Rowland M., Benet L.Z., and Graham G.G. Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1 (1973) 123-136
108. Pang K.S., and Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel-tube" model. Influence of hepatic blood flow, plasma and red cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm. 5 (1977) 625-653
109. Houston B.J. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47 (1994) 1469-1479
110. Schneider G., Coassolo P., and Lave T. Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. J. Med. Chem. 42 (1999) 5072-5076
111. Lewis D.F.V., Modi S., and Dickins M. Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab. Rev. 34 (2002) 69-82
112. Hansch C., Mekapati S.B., Kurup A., and Verma R.P. QSAR of cytochrome P450. Drug Metab. Rev. 36 (2004) 105-156
113. Ekins S., and Obach R.S. Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance. J. Pharmacol. Exp. Ther. 295 (2000) 463-473
114. Balakin K.V., Ekins S., Bugrim A., Ivanenkov Y.A., Korolev D., Nikolsky Y.V., Ivashchenko A.A., Savchuk N.P., and Nikolskaya T. Quantitative structure-metabolism relationship modeling of metabolic N-dealkylation reaction rates. Drug Metab. Dispos. 32 (2004) 1111-1120
115. Balakin K.V., Ekins S., Bugrim A., Ivanenkov Y.A., Korolev D., Nikolsky Y.V., Skorenko A.V., Ivashchenko A.A., Savchuk N.P., and Nikolskaya T. Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab. Dispos. 32 (2004) 1183-1189
116. Ekins S., de Groot M.J., and Jones J.P. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab. Dispos. 29 (2001) 936-944
117. Dedrick R., Bischoff K.B., and Zaharko D.S. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother. Rep. 54 (1970) 95-101
118. Boxenbaum H., and Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am. J. Physiol. 245 (1983) R768-R775
119. West G.B., Brown J.H., and Enquist B.J. A general model for the origin of allometric scaling laws in biology. Science 276 (1997) 122-126
120. West G.B., Brown J.H., and Enquist B.J. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284 (1999) 1677-1679
121. Wajima T., Fukumura K., Yano Y., and Oguma T. Prediction of human clearance from animal data and molecular structural parameters using multivariate regression analysis. J. Pharm. Sci. 91 (2002) 2489-2498
122. Wajima T., Fukumura K., Yano Y., and Oguma T. Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: oral clearance. J. Pharm. Sci. 92 (2003) 2427-2440
123. Yap C.W., Li Z.R., and Chen Y.Z. Quantitative structure-pharmacokinetic relationships for drug clearance by using statistical learning methods. J. Mol. Graph. Model. 24 (2005) 383-395
124. Fouchecourt M.O., Beliveau M., and Krishnan K. Quantitative structure-pharmacokinetic relationship modelling. Sci. Total Environ. 274 (2001) 125-135
125. Fouchecourt M.O., and Krishnan K. Quantitative relationship between steady-state blood concentrations and structural features of aliphatic hydrocarbons. Toxicol. Lett. 110 (1999) 177-182
126. Khor S.P., McCarthy K., Dupont M., Murray K., and Timony G. Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial. J. Pharmacol. Exp. Ther. 293 (2000) 618-624
127. Wajima T., Yano Y., Fukumura K., and Oguma T. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J. Pharm. Sci. 93 (2004) 1890-1900
128. Gobburu J.V., and Chen E.P. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. J. Pharm. Sci. 85 (1996) 505-510
129. Chow H.H., Tolle K.M., Roe D.J., Elsberry V., and Chen H. Application of neural networks to population pharmacokinetic data analysis. J. Pharm. Sci. 86 (1997) 840-845
130. Gaweda A.E., Jacobs A.A., Brier M.E., and Zurada J.M. Pharmacodynamic population analysis in chronic renal failure using artificial neural networks-a comparative study. Neural Netw. 16 (2003) 841-845
131. Urquidi-Macdonald M., Mager D.E., Mascelli M.A., Frederick B., Freedman J., Fitzgerald D.J., Kleiman N.S., and Abernethy D.R. Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. Clin. Pharmacol. Ther. 75 (2004) 60-69
132. Veng-Pedersen P., and Modi N.B. Application of neural networks to pharmacodynamics. J. Pharm. Sci. 82 (1993) 918-926
133. Elman J.L. Finding structure in time. Cogn. Sci. 14 (1990) 179-211
134. Mager D.E., and Beal M.J. Quantitative structure pharmacokinetic relationships (QSPKR) using Bayesian neural networks. Joint SIAM-SMB Conference on the Life Sciences, Raleigh, NC (2006)
135. Bonate P.L., and Howard D. Prospective allometric scaling: does the emperor have clothes?. J. Clin. Pharmacol. 40 (2000) 335-340
136. Yu L.X., and Amidon G.L. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 186 (1999) 119-125
137. Sinko P.J., Leesman G.D., and Amidon G.L. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm. Res. 8 (1991) 979-988
138. Usansky H.H., and Sinko P.J. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a). J. Pharmacol. Exp. Ther. 314 (2005) 391-399
139. Willmann S., Schmitt W., Keldenich J., Lippert J., and Dressman J.B. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47 (2004) 4022-4031
140. Gerlowski L.E., and Jain R.K. Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci. 72 (1983) 1103-1127
141. Nestorov I. Whole body pharmacokinetic models. Clin. Pharmacokinet. 42 (2003) 883-908
142. D'Souza R.W., and Boxenbaum H. Physiological pharmacokinetic models: some aspects of theory, practice and potential. Toxicol. Ind. Health 4 (1988) 151-171
143. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., and Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13 (1997) 407-484
144. Xu L., Eiseman J.L., Egorin M.J., and D'Argenio D.Z. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J. Pharmacokinet. Pharmacodyn. 30 (2003) 185-219
145. Grass G.M., and Sinko P.J. Physiologically-based pharmacokinetic simulation modelling. Adv. Drug Deliv. Rev. 54 (2002) 433-451
146. Theil F.P., Guentert T.W., Haddad S., and Poulin P. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol. Lett. 138 (2003) 29-49
147. Blakey G.E., Nestorov I.A., Arundel P.A., Aarons L.J., and Rowland M. Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. J. Pharmacokinet. Biopharm. 25 (1997) 277-312
148. Nestorov I., Aarons L., and Rowland M. Quantitative structure-pharmacokinetics relationships: II. A mechanistically based model to evaluate the relationship between tissue distribution parameters and compound lipophilicity. J. Pharmacokinet. Biopharm. 26 (1998) 521-545
149. Nestorov I.S., Hadjitodorov S.T., Petrov I., and Rowland M. Empirical versus mechanistic modelling: comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetic relationships of a homologous series of barbiturates. AAPS PharmSci 1 (1999) E17
150. DeJongh J., Verhaar H.J., and Hermens J.L. A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch. Toxicol. 72 (1997) 17-25
151. Poulin P., and Theil F.P. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. 89 (2000) 16-35
152. Poulin P., Schoenlein K., and Theil F.P. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J. Pharm. Sci. 90 (2001) 436-447
153. Poulin P., and Theil F.P. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 91 (2002) 1358-1370
154. Poulin P., and Theil F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91 (2002) 129-156
155. Luttringer O., Theil F.P., Poulin P., Schmitt-Hoffmann A.H., Guentert T.W., and Lave T. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J. Pharm. Sci. 92 (2003) 1990-2007
156. Parrott N., Paquereau N., Coassolo P., and Lave T. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J. Pharm. Sci. 94 (2005) 2327-2343
157. Jones H.M., Parrott N., Jorga K., and Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 45 (2006) 511-542
158. Liu H.X., Yao X.J., Zhang R.S., Liu M.C., Hu Z.D., and Fan B.T. Prediction of the tissue/blood partition coefficients of organic compounds based on the molecular structure using least-squares support vector machines. J. Comput. Aided Mol. Des. 19 (2005) 499-508
159. Gueorguieva II, Nestorov I.A., and Rowland M. Fuzzy simulation of pharmacokinetic models: case study of whole body physiologically based model of diazepam. J. Pharmacokinet. Pharmacodyn. 31 (2004) 185-213
160. Roy J.J., and Varin F. Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship. Br. J. Anaesth. 93 (2004) 241-248
161. Yang R.S., Thomas R.S., Gustafson D.L., Campain J., Benjamin S.A., Verhaar H.J., and Mumtaz M.M. Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling. Environ. Health Perspect. 106 Suppl 6 (1998) 1385-1393
162. Levy G. Impact of pharmacodynamic variability on drug delivery(1). Adv. Drug Deliv. Rev. 33 (1998) 201-206
163. Mager D.E., Wyska E., and Jusko W.J. Diversity of mechanism-based pharmacodynamic models. Drug Metab. Dispos. 31 (2003) 510-518
164. Dayneka N.L., Garg V., and Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21 (1993) 457-478
165. Rohatagi S., Bye A., Mackie A.E., and Derendorf H. Mathematical modeling of cortisol circadian rhythm and cortisol suppression. Eur. J. Pharm. Sci. 4 (1996) 341-350
166. Derendorf H., Mollmann H., Barth J., Mollmann C., Tunn S., and Krieg M. Pharmacokinetics and oral bioavailability of hydrocortisone. J. Clin. Pharmacol. 31 (1991) 473-476
167. Derendorf H., Hochhaus G., Mollmann H., Barth J., Krieg M., Tunn S., and Mollmann C. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J. Clin. Pharmacol. 33 (1993) 115-123
168. Jusko W.J. Relationship of dose- and time-dependent corticosteroid responses to receptor turnover. In: Schleimer R.P., O'Byrne P.M., Szefler S.J., and Brattsand R. (Eds). Inhaled Steroids in Asthma (2001), Marcel Dekker, Inc., New York 95-112
169. Wolff M.E., Baxter J.D., Kollman P.A., Lee D.L., Kuntz I.D., Bloom E., Matulich D.T., and Morris J. Nature of steroid-glucocorticoid receptor interactions: thermodynamic analysis of the binding reaction. Biochemistry 17 (1978) 3201-3208
170. Ramakrishnan R., DuBois D.C., Almon R.R., Pyszczynski N.A., and Jusko W.J. Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J. Pharmacokinet. Pharmacodyn. 29 (2002) 1-24
171. Mager D.E., Pyszczynski N.A., and Jusko W.J. Integrated QSPR-pharmacodynamic model of genomic effects of several corticosteroids. J. Pharm. Sci. 92 (2003) 881-889
172. Sun Y.N., DuBois D.C., Almon R.R., and Jusko W.J. Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J. Pharmacokinet. Biopharm. 26 (1998) 289-317
173. Jusko W.J., Pyszczynski N.A., Bushway M.S., D'Ambrosio R., and Mis S.M. Fifteen years of operation of a high-performance liquid chromatographic assay for prednisolone, cortisol and prednisone in plasma. J. Chromatogr., B Biomed. Appl. 658 (1994) 47-54
174. Diamondstone T.I. Assay of tyrosine aminotransferase activity by conversion of p-hydroxy-phenylpyruvate to p-hydroxybenzaldehyde. Anal. Biochem. 16 (1966) 395-401
175. Nichols A.I., Boudinot F.D., and Jusko W.J. Second generation model for prednisolone pharmacodynamics in the rat. J. Pharmacokinet. Biopharm. 17 (1989) 209-227
176. Nichols A.I., and Jusko W.J. Receptor-mediated prednisolone pharmacodynamics in rats: model verification using a dose-sparing regimen. J. Pharmacokinet. Biopharm. 18 (1990) 189-208
177. Yao Z., DuBois D.C., Almon R.R., and Jusko W.J. Modeling circadian rhythms of glucocorticoid receptor and glutamine synthetase expression in rat skeletal muscle. Pharm. Res. 23 (2006) 670-679
178. Mahmood I., and Green M.D. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin. Pharmacokinet. 44 (2005) 331-347
179. Lobo E.D., Hansen R.J., and Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93 (2004) 2645-2668